<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00479934</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2006/05</org_study_id>
    <secondary_id>2006/017</secondary_id>
    <nct_id>NCT00479934</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Imatinib in Scleroderma</brief_title>
  <acronym>SCLEROGLIVEC</acronym>
  <official_title>Phase II Randomized Double Blind Clinical Trial of'Imatinib Mesylate STI571 (Glivec®) Versus Placebo in Patients With Severe Cutaneous Scleroderma or Systemic Sclerosis With Severe Cutaneous Involvement.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In vitro studies have shown that imatinib 1mM inhibits strongly the growth of cutaneous
      fibroblasts. The hypothesis is that imatinib inhibits PDGFR which is known to be a potential
      target for the molecule, as recently also proposed after the discovery of autoantibodies
      activating the PDGF receptors. Recent data indicate that TGFb is also a potential target of
      imatinib. Cutaneous scleroderma is characterized by progressive cutaneous fibrosis caused by
      hyperactive dermal fibroblasts. Since no established treatment for skin sclerosis in
      scleroderma is currently available. This study will test the safety and efficacy of imatinib
      in the treatment of patients with scleroderma and severe cutaneous involvement.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will test the efficacy and tolerance of patients with a high score of induration
      (modified Rodnan score &gt; 20/54) Comparison : 34 patients with severe forms of cutaneous
      involvement will be evaluated in a double blind RCT comparing imatinib 400mg/j and placebo in
      a 6 month period. Efficacy will be assessed using a cutaneous induration scale and skin
      biopsy, and quality of life questionnaires.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compare the efficacy of imatinib mesylate vs placebo based on the percent variation of modified Rodnan score (0-51) between inclusion and 6-month visits.</measure>
    <time_frame>6 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare efficacy of imatinib mesylate vs placebo based on the percent variation of modified Rodnan score between the inclusion and the various time points of follow-up.</measure>
    <time_frame>1, 3 and 12 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess skin thickness at inclusion and at 6 months using skin biopsies</measure>
    <time_frame>6 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of quality of life using DLQI (Dermatology Quality of Life Index) and HAQ (Health Assessment Questionnaire).</measure>
    <time_frame>At 1, 3, 6 month and 1 year,</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess tolerance of treatment (clinical and laboratory monitoring of side effects)</measure>
    <time_frame>All along the trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess effects of treatment on non cutaneous symptoms in systemic sclerosis patients</measure>
    <time_frame>All along the trial</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Scleroderma, Localized</condition>
  <condition>Scleroderma, Systemic</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 month treatment with Imtinib 400mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>6 month treatment with Placebo 400mg/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>imatinib mesylate</intervention_name>
    <description>6 month treatment with 400mg/day (per os)</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  More than 18 years old

          -  Documented diagnostic of scleroderma (systemic or cutaneous)

          -  Severe cutaneous sclerodermia or systemic sclerodermia with m-Rodnan score &gt; 20/51

          -  Ejection fraction of more than 45 per cent at cardiac ultrasound pre-inclusion study

          -  Woman with efficient contraceptive method during trail treatment and during 3 month
             after the end of trial treatment

          -  All female patients with reproductive potential must have a negative pregnancy test
             (serum or urine) within the 7 days prior to enrolment

          -  Affiliated or profit patient of a social security system

          -  Signed informed consent

        Exclusion Criteria:

          -  new systemic treatment, potentially interfering with disease progression, beginning 3
             months prior the start trial treatment

          -  Patient with isolated cutaneous scleroderma treated with a drug potentially
             interfering with the course of the disease 4 weeks before starting the trial (Systemic
             corticosteroids, methotrexate, cyclophosphamide, bosentan)

          -  Scleroderma &quot; en coup de sabre &quot;

          -  Severe organ failure or anomaly of blood chemistry/hematology (bilirubin, SGOT, SGPT,
             creatinine &gt; 1,5 ´ upper normal limit, polymorphonuclear granulocytes less than
             1*10*9/l or platelets less than 50*10*9/l),

          -  Ongoing cancer

          -  Ejection fraction ≤ 45 per cent at cardiac ultrasound pre inclusion study

          -  myocardial infarction of less than 6 mois at pre inclusion visit

          -  Non controlled chronic illness (diabetes, chronic kidney failure, chronic hepatitis,
             HIV infection),

          -  Major surgery less than two weeks before inclusion

          -  Pregnancy or lactation

          -  Absence of validated contraception in childbearing women.

          -  Contraindication to imatinib mesylate treatment as specified in product specifications

          -  Non observance anticipated and absence of informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alain TAIEB, Pr.</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital, Bordeaux, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Geneviève CHENE, Pr</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital, Bordeaux, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alian TAIEB, Pr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Bordeaux, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Service de Dermatologie et services de médecine interne et vasculaire - Hôpital St André - CHU de Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Rhumatologie, Hôpital Pellegrin-Tondu CHU de Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Dermatologie - CHG Libourne</name>
      <address>
        <city>Libourne</city>
        <zip>33500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de dermatologie - CHU de Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Médecin interne - Hôpital central</name>
      <address>
        <city>Nancy</city>
        <zip>54035</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Médecine interne - Hôpital Saint Louis</name>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Dermatologie - CHG Périgueux</name>
      <address>
        <city>Perigueux</city>
        <zip>24000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Dermatologie - service de médecine interne et vasculaire - hopital haut Lévêque - av.de magellan</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Rhumatologie - CHU de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Dermatologie - CHU de Toulouse - Hopital Purpan</name>
      <address>
        <city>Toulouse</city>
        <zip>31059 Toulouse Cedex</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Médecine interne - CHU de Tours</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Néphrologie et Médecine interne - CH de Valenciennes</name>
      <address>
        <city>Valenciennes</city>
        <zip>59322</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 29, 2007</study_first_submitted>
  <study_first_submitted_qc>May 29, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 30, 2007</study_first_posted>
  <last_update_submitted>March 3, 2011</last_update_submitted>
  <last_update_submitted_qc>March 3, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 4, 2011</last_update_posted>
  <responsible_party>
    <name_title>Jean-Pierre LEROY / Clinical Research and Innovation Director</name_title>
    <organization>University Hospital, Bordeaux</organization>
  </responsible_party>
  <keyword>scleroderma</keyword>
  <keyword>imatinib</keyword>
  <keyword>PDGFR</keyword>
  <keyword>Rodnan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Scleroderma, Systemic</mesh_term>
    <mesh_term>Scleroderma, Diffuse</mesh_term>
    <mesh_term>Scleroderma, Localized</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imatinib Mesylate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

